Ask AI
ProCE Banner Activity

Responder a las preguntas clave en el tratamiento óptimo de los pacientes con leucemia linfocítica crónica recidivante/refractaria

Clinical Thought

En esta actividad, los expertos abordan cuestiones clave en el cuidado de los pacientes con leucemia linfocítica crónica (LLC) recidivante/refractaria (R/R), tal y como se debatió durante un seminario web en directo. Estas respuestas proporcionan información práctica y que los médicos que se encuentran muy ocupados pueden utilizar en la clínica. 

Released: December 20, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Othman Al-Sawaf, MD, PhD

Attending Hematologist & Medical Oncologist
Emmy Noether Group Leader
Integrated Cancer Research Laboratory
Department I of Internal Medicine, CECAD Research Center
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD, PhD: consultant/advisor/speaker: AbbVie, Adaptive, Ascentage, AstraZeneca, BeiGene, Genmab, Gilead, Hikma, Janssen, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Professor of Internal Medicine
Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeOne, Bristol Myers Squibb, Dava Oncology, Incyte, Invivyd, Loxo Oncology, Miltenyi, Pierre Fabre; researcher: AbbVie/Pharmacyclics, Actinium; data and safety monitoring board: Ascentage, AstraZeneca, Caribou.

Alessandra Tedeschi, MD

Consultant in Hematology
Niguarda Cancer Center
ASST GOM Niguarda
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.